Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

25 Apr 2017

Abstract excerpt

B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer and the prognosis of children with relapsed or therapy refractory disease remains a challenge. Treatment with chimeric antigen receptor-modified T cells targeting the CD19 antigen (CART-19 therapy) has been presented as a promising approach toward improving the outcome of relapsed or refractory disease. However, 10%-20% of the patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28441264
DOI: 10.1097/cji.0000000000000169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial DiagnosisPMID 28441264Read ↗

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.Semantic proximity Read ↗

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19Semantic proximity Read ↗

Deregulation in binding and expression of RNA binding proteins as a mechanism of CD19-negative B-ALLSemantic proximity Read ↗

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitroSemantic proximity Read ↗

Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL.Semantic proximity Read ↗

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemiaSemantic proximity Read ↗

Relapse/refractory paediatric B-ALL case with CD19 - phenotype switching indicating the importance of appropriate diagnostics approach and targeted treatment adjustment – case reportSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling <i>CD19</i> splicing and CART-19 therapy resistanceSemantic proximity Read ↗

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy eraSemantic proximity Read ↗

CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—Immunophenotypic challenges in diagnosis and monitoring: A study of three casesSemantic proximity Read ↗

Treatment Outcome of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse by Anti-CD19 CAR-TSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.